Aldeyra Therapeutics (ALDX) Total Debt (2013 - 2026)

Aldeyra Therapeutics' Total Debt history runs 14 years deep, the most recent figure standing at $15.3 million for Q1 2026.

• Quarterly Total Debt rose 1.33% year-over-year to $15.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.3 million (up 1.33% YoY) and the FY2025 annual result came in at $30.2 million, up 101.24% from the prior year.
• Total Debt was $15.3 million for Q1 2026 at Aldeyra Therapeutics, down from $30.2 million in the prior quarter.
• Across five years, Total Debt topped out at $30.2 million in Q4 2025 and bottomed at $15.0 million in Q1 2022.
• A 5-year average of $18.1 million and a median of $15.3 million in 2026 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2023 — Total Debt slumped 41.28% — and 2025, when it surged 101.24%.
• Aldeyra Therapeutics' Total Debt stood at $15.8 million in 2022, then retreated by 4.35% to $15.1 million in 2023, then fell by 0.76% to $15.0 million in 2024, then jumped by 101.24% to $30.2 million in 2025, then slumped by 49.42% to $15.3 million in 2026.
• Business Quant data shows ALDX's Total Debt at $15.3 million in Q1 2026, $30.2 million in Q4 2025, and $30.2 million in Q3 2025.